ArticleTherapeutic advances in pulmonary and critical care medicine
Incidence of Healthcare-Associated Infections in Patients on Extracorporeal Membrane Oxygenation Secondary to Respiratory or Cardiac Failure: A Retrospective Cohort Study.
Article in Therapeutic advances in pulmonary and critical care medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) is a life support technique used in patients with respiratory or cardiac failure. Despite the increased use of ECMO, the incidence and risk factors for healthcare-associated infections (HAIs) are highly variable and dependent on healthcare systems. Objectives: To describe the incidence of HAIs in patients on ECMO secondary to respiratory or cardiac failure, the microorganisms involved, and antibiotic resistance, and to identify risk factors associated with the incidence of HAIs. Design: Single-center retrospective cohort study. Methods: We included adult patients (15 years or older) on venovenous ECMO (VV-ECMO) or venoarterial ECMO (VA-ECMO) secondary to respiratory or cardiac failure and who were admitted to the Instituto Nacional del Tórax (Santiago, Chile) between 2022 and 2024. We included confirmed HAIs related to the ECMO procedure between 24 h after ECMO initiation and 48 h after its withdrawal. Microbiological confirmation was obtained through positive cultures, positive pneumonia FilmArray results, or elevated bronchoalveolar lavage galactomannan levels (> 1 mg/L). The data were collected by two researchers and verified by a third party. We conducted multivariable logistic regression to identify risk factors for HAI. Results: Seventy-two patients were included in our study, with a median age of 46 years (IQR 29.75-59) and 55.56% male. Thirty-eight (52.78%) patients had confirmed HAI. We identified 70 microorganisms, with gram-negative bacilli being the most prevalent. Among these, the majority were Conclusion: Half of the patients on ECMO secondary to respiratory or cardiac failure developed HAI. The most frequent microorganisms were gram-negative bacteria, and the primary antibiotic resistance detected was for carbapenems. The only independent risk factor for developing HAI was the length of stay on ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.